Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Features

Cardiac Transplant in Midst of ‘Revolution,’ but Public Trust Is Fragile

Michael O'Riordan

October 17, 2025

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

News Conference News HFSA 2023

Survey Offers Clues to Waning Appeal of Acute HF/Transplant Fellowships

Shelley Wood

October 13, 2023

News Features

Heart Failure Care Has a Pipeline Problem: What’s the Fix?

Shelley Wood

December 20, 2022

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

L.A. McKeown

October 07, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Conference News STS 2022

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

Michael O'Riordan

February 04, 2022

News Conference News STS 2022

Modified Surgical MV Repair Stands Up to Replacement

Michael O'Riordan

February 03, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Conference News ACC 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

Shelley Wood

May 15, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Conference News ESC 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Michael O'Riordan

August 29, 2020

News Daily News

Impella Heart Pumps Get Expanded Indication for Cardiogenic Shock in Setting of Cardiomyopathy

Todd Neale

February 13, 2018

Presentation TCT 2014

Hemodynamics of Dynamic Obstruction

Presenter: John S. Douglas Jr, Sherif F. Nagueh, Howard C. Herrmann, James B. Hermiller Jr

September 16, 2014

Advertisement

Cardiac Transplant in Midst of ‘Revolution,’ but Public Trust Is Fragile

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Survey Offers Clues to Waning Appeal of Acute HF/Transplant Fellowships

Heart Failure Care Has a Pipeline Problem: What’s the Fix?

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

Modified Surgical MV Repair Stands Up to Replacement

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

‘Enormous’ QoL Improvements With Mavacamten in HCM

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Impella Heart Pumps Get Expanded Indication for Cardiogenic Shock in Setting of Cardiomyopathy

Hemodynamics of Dynamic Obstruction

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content